SMi is thrilled to present the return of its 4th annual Immunogenicity conference and exhibition, taking place in London on the 12th – 13th June 2017.
The immunogenicity market has seen considerable progression over recent years, with innovative developments apparent in predicting and controlling immunogenicity. However the industry is still subject to complex hurdles and challenges.
This year’s conference will provide attendees with a thorough understanding of the continued need for harmonisation across risk assessments and data reporting, as well as guidance for clinical trial design. Speakers will offer deep exploration of the regulations surrounding immunogenicity testing, from the UK, Europe, and USA, giving exclusive opportunity for discussion and debate with key regulatory experts. With focus on delivering true value for all delegates in attendance, Immunogenicity 2017 will identify and solve key challenges for industry experts. Insight into aggregations, next generation biologics, novel assays, humanisation of bio-therapeutics, and improvements to accurate risk assessment will be complemented by high level case studies.
CONFERENCE HIGHLIGHTS:
. Guidance on UK, EU and USA regulations surrounding immunogenicity and best practice risk assessment
. Targeted focus on immunogenicity; identifying, addressing and removing challenges to industry
. Highlight best practice risk assessment and mitigation through high level case studies
. Explore novel and innovative approaches to reducing immunogenicity
. Spotlight on new technology; Humanising proteins and new biotherapeutic solutions
. Personalising treatments with next generation biologic drugs
The immunogenicity market has seen considerable progression over recent years, with innovative developments apparent in predicting and controlling immunogenicity. However the industry is still subject to complex hurdles and challenges.
This year’s conference will provide attendees with a thorough understanding of the continued need for harmonisation across risk assessments and data reporting, as well as guidance for clinical trial design. Speakers will offer deep exploration of the regulations surrounding immunogenicity testing, from the UK, Europe, and USA, giving exclusive opportunity for discussion and debate with key regulatory experts. With focus on delivering true value for all delegates in attendance, Immunogenicity 2017 will identify and solve key challenges for industry experts. Insight into aggregations, next generation biologics, novel assays, humanisation of bio-therapeutics, and improvements to accurate risk assessment will be complemented by high level case studies.
CONFERENCE HIGHLIGHTS:
. Guidance on UK, EU and USA regulations surrounding immunogenicity and best practice risk assessment
. Targeted focus on immunogenicity; identifying, addressing and removing challenges to industry
. Highlight best practice risk assessment and mitigation through high level case studies
. Explore novel and innovative approaches to reducing immunogenicity
. Spotlight on new technology; Humanising proteins and new biotherapeutic solutions
. Personalising treatments with next generation biologic drugs
